분자 감염증 진단 시장 : 전략적 인사이트 및 예측(2026-2035년)

The Molecular Infectious Disease Diagnostics Market is expected to grow at a CAGR of 8.5% from a market value of USD 10.6 billion in 2026 to USD 22.1 billion in 2035.

The molecular infectious disease diagnostics market is undergoing significant transformation driven by the paradigm shift toward rapid, accurate, and comprehensive pathogen detection. The market's evolution is characterized by the growing recognition that molecular confirmation is essential for timely therapeutic decision-making, antimicrobial stewardship, and public health surveillance. The convergence of polymerase chain reaction technologies, isothermal amplification, next-generation sequencing, and artificial intelligence is enabling faster, more sensitive, and increasingly multiplexed infectious disease testing. Healthcare systems are prioritizing molecular diagnostics because infectious diseases frequently present with overlapping symptoms, and rapid pathogen identification reduces unnecessary antimicrobial exposure and improves patient outcomes. The expansion of multiplex syndromic testing panels is transforming clinical laboratory workflows by enabling simultaneous detection of numerous pathogens from a single specimen. Public health agencies are expanding genomic surveillance infrastructure, increasing demand for high-throughput molecular platforms capable of detecting emerging pathogens and monitoring antimicrobial resistance. The market is witnessing significant investment in automated sample-to-answer systems, decentralized molecular testing, and integrated digital diagnostics, positioning molecular infectious disease diagnostics as a critical component of modern healthcare delivery and pandemic preparedness.

Market Drivers

• The increasing burden of infectious diseases represents the primary driver for the molecular infectious disease diagnostics market. Rapid diagnosis directly influences treatment decisions because infectious diseases frequently progress before conventional microbiological confirmation becomes available. Healthcare providers are increasingly adopting molecular diagnostics as delayed pathogen identification prolongs empirical therapy and increases unnecessary antimicrobial exposure. Traditional culture methods remain clinically important, yet longer turnaround times limit their usefulness during acute disease management. Diagnostic manufacturers are expanding rapid PCR panels, automated systems, and resistance detection assays that support antimicrobial stewardship programs, resulting in sustained growth in molecular diagnostic utilization. Multiplex syndromic testing is further accelerating market growth by transforming clinical laboratory workflows. Clinical laboratories require technologies capable of simultaneously detecting numerous pathogens because respiratory, gastrointestinal, and bloodstream infections often present with overlapping clinical manifestations. Demand is shifting toward multiplex PCR assays as laboratories attempt to improve efficiency while reducing repetitive single-target testing. Larger diagnostic menus also reduce specimen utilization and shorten diagnostic pathways. Manufacturers are responding by introducing broader syndromic panels with improved automation and integrated software. Government investment in disease surveillance is supporting market expansion through infrastructure development. National surveillance systems require standardized molecular testing because outbreak response increasingly depends on rapid pathogen identification and genomic characterization. Governments are continuing to invest in molecular laboratory infrastructure following lessons learned during the COVID-19 pandemic. Public health agencies also require scalable testing capacity for influenza, respiratory syncytial virus, tuberculosis, hepatitis, antimicrobial resistance, and emerging infectious diseases. Diagnostic manufacturers continue developing high-throughput molecular systems capable of supporting both routine diagnostics and emergency response. Automation and digital laboratory integration are improving testing capacity and workflow efficiency. Clinical laboratories face workforce shortages while diagnostic volumes continue increasing. Automated molecular platforms reduce manual intervention because integrated extraction, amplification, and detection simplify laboratory workflows. Healthcare systems are consequently investing in sample-to-answer instruments, digital connectivity, and laboratory information system integration.

Market Restraints

• High capital investment requirements for automated molecular diagnostic platforms limit adoption among smaller hospitals and laboratories with constrained budgets. The substantial upfront costs for instrumentation create barriers for resource-constrained settings. Regulatory approval processes and evolving quality requirements increase commercialization timelines for novel molecular infectious disease assays. The rigorous validation requirements delay market entry for innovative technologies. Molecular diagnostics identify pathogen nucleic acids but often require complementary microbiological testing for comprehensive antimicrobial susceptibility assessment, limiting complete replacement of conventional culture methods. The need for integrated workflows creates additional complexity for laboratories. Shortages of specialized laboratory professionals and molecular diagnostics expertise constrain efficient utilization of advanced platforms, limiting scalability in many healthcare settings.

Technology and Segment Insights

• The technology landscape is characterized by the growing importance of multiplex molecular diagnostics and integrated testing workflows. PCR remains the dominant molecular technology because of its established analytical performance and extensive regulatory acceptance. Clinical laboratories are expanding PCR utilization beyond single-pathogen detection toward multiplex respiratory, gastrointestinal, bloodstream, and sexually transmitted infection panels that improve diagnostic efficiency. Real-time PCR (qPCR) provides quantitative detection for viral load monitoring and disease management. Digital PCR offers ultra-sensitive detection for low-abundance targets and rare mutation identification. Isothermal amplification technologies are gaining adoption for point-of-care and decentralized testing due to simplified instrumentation requirements. NGS is expanding for comprehensive pathogen surveillance, outbreak investigation, and antimicrobial resistance monitoring. The segment analysis reveals that reagents and consumables constitute the recurring revenue foundation because every molecular assay requires standardized extraction kits, amplification reagents, primers, probes, enzymes, quality controls, and disposable cartridges. Testing volumes are continuing to increase as hospitals expand syndromic testing and national surveillance programs strengthen molecular screening capacity. Respiratory infections represent the most established application segment because influenza, RSV, SARS-CoV-2, and numerous bacterial pathogens require rapid differentiation despite similar clinical presentation. Seasonal outbreaks are increasing laboratory testing demand while hospitals attempt to optimize patient isolation and antimicrobial utilization. Sexually transmitted infections, healthcare-associated infections, gastrointestinal infections, and hepatitis represent significant growth segments. Hospitals and clinical laboratories represent key end-user segments, with academic and research institutes playing a crucial role in assay development and validation. Point-of-care molecular diagnostics are expanding across decentralized healthcare settings. The integration of AI is becoming increasingly important because molecular diagnostic platforms generate complex data requiring efficient interpretation. AI is supporting result interpretation, quality control, and laboratory workflow optimization.

Competitive and Strategic Outlook

• The competitive landscape features established molecular diagnostics and life science companies alongside specialized infectious disease and point-of-care providers. F. Hoffmann-La Roche is strategically distinguished by its comprehensive cobas molecular diagnostics ecosystem, integrating high-throughput PCR platforms with a broad infectious disease assay portfolio for centralized laboratories, continuing to expand automation, digital laboratory integration, and syndromic testing capabilities. Abbott differentiates itself through its diversified molecular diagnostics portfolio, combining centralized laboratory systems with rapid molecular testing platforms, continuing to expand infectious disease assay offerings while strengthening decentralized testing capabilities. Danaher leverages its operating companies, particularly Cepheid and Beckman Coulter, to provide integrated molecular diagnostics across centralized and near-patient settings, focusing on rapid PCR technologies, workflow automation, and continuous assay expansion. bioMerieux specializes in clinical microbiology and molecular infectious disease diagnostics, combining syndromic PCR testing with antimicrobial stewardship solutions, focusing on improving laboratory efficiency and accelerating pathogen identification for critical care settings. Hologic is recognized for its Panther molecular diagnostics platform, supporting high-throughput, fully automated infectious disease testing, continuing to expand its assay menu, particularly for sexually transmitted infections and respiratory diseases. QIAGEN differentiates itself through integrated sample preparation technologies and the QIAstat-Dx multiplex syndromic testing platform. Thermo Fisher Scientific offers a broad portfolio of molecular diagnostic instruments, PCR reagents, and genomic analysis solutions. BD combines molecular diagnostics with microbiology and specimen management solutions. Companies are pursuing product portfolio expansion through innovation in multiplex syndromic panels, rapid point-of-care molecular tests, antimicrobial resistance detection, and AI-enabled interpretation software. Strategic collaborations between diagnostic manufacturers, healthcare providers, and public health agencies are increasing, driven by the need for surveillance and outbreak preparedness. Recent key developments include Bruker launching MyGenius PRO, a fully automated PCR-based molecular diagnostics system delivering up to 144 results in 8 hours. Co-Diagnostics and its Saudi Arabia joint venture unveiled an automated manufacturing line for molecular diagnostic test kits. bioMerieux launched VetFire for equine veterinarians. Synthego announced its entry into the molecular biology and clinical diagnostic reagents market. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

• The molecular infectious disease diagnostics market is positioned for sustained growth driven by the convergence of infectious disease burden, multiplex testing adoption, government surveillance investment, and laboratory automation. The transition from single-pathogen testing toward comprehensive syndromic and multiplex diagnostic platforms represents a fundamental shift in infectious disease management. While challenges related to high capital costs, regulatory complexity, and workforce shortages persist, strategic investments in technology, automation, and partnerships are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with molecular infectious disease diagnostics evolving into a critical component of modern healthcare delivery, supporting rapid pathogen identification, antimicrobial stewardship, outbreak preparedness, and genomic surveillance across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global Molecular Infectious Disease Diagnostics Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Infectious Disease Diagnostics Industry Overview
• 3.3 Evolution of Molecular Infectious Disease Diagnostics
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Infectious Disease Burden and Unmet Diagnostic Needs
• 3.8 Disease Prevalence and Diagnosed Patient Population Analysis
• 3.9 Testing Volume Analysis
• 3.10 Diagnostic Workflow and Patient Journey Analysis
• 3.11 Molecular Diagnostics Adoption Across Healthcare Settings

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Molecular Diagnostic Technologies
• 6.2 Product Innovation Landscape
• 6.3 Clinical Trial Analysis
• 6.4 Diagnostic Pipeline Analysis
• 6.5 Technology Roadmap
• 6.6 Artificial Intelligence Integration in Molecular Diagnostics
• 6.7 Digital Health and Laboratory Informatics Integration

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global Molecular Infectious Disease Diagnostics Market Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Test Type
• 8.3 Analysis by Pathogen Type
• 8.4 Analysis by Sample Type
• 8.5 Analysis by Clinical Application
• 8.6 Analysis by Testing Setting

9. Global Molecular Infectious Disease Diagnostics Market Segment Analysis (2021-2035)

• 9.1 By Technology
  • 9.1.1 Polymerase Chain Reaction (PCR)
    • 9.1.1.1 Conventional PCR
    • 9.1.1.2 Real-Time PCR (qPCR)
    • 9.1.1.3 Digital PCR (dPCR)
  • 9.1.2 Isothermal Nucleic Acid Amplification Technologies
  • 9.1.3 Next-Generation Sequencing (NGS)
  • 9.1.4 DNA Microarrays
  • 9.1.5 Other Molecular Technologies
• 9.2 By Test Type
  • 9.2.1 Laboratory-Based Molecular Diagnostics
  • 9.2.2 Point-of-Care Molecular Diagnostics
• 9.3 By Product
  • 9.3.1 Instruments
  • 9.3.2 Reagents & Consumables
  • 9.3.3 Software & Services
• 9.4 By Disease Indication
  • 9.4.1 Respiratory Infections
  • 9.4.2 Sexually Transmitted Infections (STIs)
  • 9.4.3 Healthcare-Associated Infections (HAIs)
  • 9.4.4 Gastrointestinal Infections
  • 9.4.5 Hepatitis
  • 9.4.6 Other Infectious Diseases
• 9.6 By Sample Type
  • 9.6.1 Blood
  • 9.6.2 Respiratory specimens (Sputum & Swabs)
  • 9.6.3 Urine
  • 9.6.4 Stool
  • 9.6.5 6 Saliva
  • 9.6.6 Other Sample Types
• 9.7 By End User
  • 9.7.1 Hospitals
  • 9.7.2 Clinical Laboratories
  • 9.7.3 Academic & Research Institutes
  • 9.7.4 Other End Users

10. Global Molecular Infectious Disease Diagnostics Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global Molecular Infectious Disease Diagnostics Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Netherlands
• 11.9 Japan
• 11.10 China
• 11.11 India
• 11.12 South Korea
• 11.13 Australia
• 11.14 Brazil
• 11.15 Mexico
• 11.16 Saudi Arabia
• 11.17 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 Abbott Laboratories
• 13.3 Danaher Corporation
• 13.4 bioMerieux SA
• 13.5 Hologic, Inc.
• 13.6 QIAGEN N.V.
• 13.7 Thermo Fisher Scientific Inc.
• 13.8 Becton, Dickinson and Company (BD)
• 13.9 Siemens AG
• 13.10 Bio-Rad Laboratories, Inc.

14. Global Molecular Infectious Disease Diagnostics Market Commercial Forecast Analysis

• 14.1 PCR-Based Molecular Diagnostics
• 14.2 Isothermal Amplification-Based Diagnostics
• 14.3 Next-Generation Sequencing-Based Infectious Disease Diagnostics
• 14.4 Syndromic Multiplex Molecular Panels
• 14.5 Point-of-Care Molecular Diagnostic Systems
• 14.6 CRISPR-Based Molecular Diagnostic Platforms

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends